Dermatan sulfate - Mediolanum

Drug Profile

Dermatan sulfate - Mediolanum

Alternative Names: Dermatan sulfate; MF 701; Mistral

Latest Information Update: 28 May 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mediolanum
  • Developer Medinfar; Mediolanum; Vecchi & C. Piam
  • Class Antithrombotics; Glycosaminoglycans; Small molecules
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Venous thromboembolism
  • Discontinued Heparin-induced thrombocytopenia and thrombosis syndrome; Thrombosis

Most Recent Events

  • 07 Dec 2001 Investigation in Heparin-induced thrombocytopenia and thrombosis syndrome in Italy (Injection)
  • 27 Sep 1999 Launched for Venous thromboembolism (Prevention) in Italy (Injection)
  • 27 Sep 1999 A clinical study has been added to the Thromboses pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top